Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
University of California, San Diego · VA San Diego Healthcare System · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
912
total citations
- FWCI
- 38.62
- Percentile
- 100%
- References
- 58
Citations per year
Authors
13- SMSunder MudaliarCorresponding
University of California, San Diego, VA San Diego Healthcare System
- RRRobert R. Henry
University of California, San Diego, VA San Diego Healthcare System
- AJArun J. Sanyal
Virginia Commonwealth University
- LMLinda Morrow
Profil Institute for Clinical Research, Precision Research Institute
- HMHanns–Ulrich Marschall
University of Gothenburg
Topics & keywords
Topics
Keywords
- Farnesoid X receptor
- Internal medicine
- Endocrinology
- Obeticholic acid
- Insulin resistance
- Nonalcoholic fatty liver disease
- Medicine
- Insulin
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.